ECDC training programme workshop on “Development of public health programmes for prevention and control of seasonal influenza” took place in Stockholm 8-10 October 2012.
A report in the US Centers for Disease Control and Prevention (CDC) MMWR this week describes the investigation of mild respiratory illness among swine and people at a county fair in Indiana, USA between 8 and 14 July 2012. This is an important report as it is very clearly documents simultaneous detection of H3N2v influenza viruses in humans and swine in close contact.
The 1918 pandemic continues to provide a rich source of studies of the clinical impact of those novel viruses which between 1918 and 1920 killed up to 50 million people world-wide. These two recent studies first shows autopsy results among military recruits who died from the first influenza pandemic of the 20th century and the second suggests the impact on births.
On 3 October 2011 European Centre for Disease Prevention and Control (ECDC) and representatives of the European Vaccine Manufacturers met at ECDC in Stockholm for a regular scheduled meeting about the use of vaccines for prevention of seasonal and pandemic influenza. ECDC Director Marc Sprenger opened the meeting and ECDC influenza experts held different presentations, such as burden of influenza disease in the EU, risk groups for severe influenza disease, personal protective measures, pandemic influenza preparedness, seasonal influenza vaccines, communication.
The Declarations of Interest for ECDC Influenza Staff and the ECDC Director are available here under ECDC Transparency.
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
2 papers are reviewed: A Novel Risk Factor for a Novel Virus: Obesity and 2009 Pandemic Influenza A (H1N1) and Morbid Obesity as a Risk Factor for Hospitalization and Death Due to 2009 Pandemic Influenza A(H1N1) Disease.
Each year in February WHO convenes a meeting with advisers from the WHO Influenza Collaborating Centres and Essential Reference laboratories in order to achieve consensus and advise WHO on the optimal formulation of seasonal influenza vaccines for the next influenza season.